

Annex 4 - Specific adverse drug reaction follow-up forms

This annex contains the specific adverse event targeted follow-up checklists used to collect additional data for the following deferasirox RMP risks:

- Renal disorders (increased serum creatinine, acute renal failure, renal tubular disorders [acquired Fanconi's syndrome])
- Increased liver transaminases and hepatic failure
- Gastrointestinal hemorrhage, ulcer, and esophagitis
- Hearing loss
- Lens opacities, retinal changes and optic neuritis
- Exjade severe skin reaction

Targeted follow-up checklists:

- **Exjade Serum Creatinine Increase checklist**

- In addition to collecting routine information for this adverse event, please ensure the following additional information is provided and/or confirmed.

•

- **Information on Dose of Exjade:**

Dose in mg/kg/day	Dates of treatment (dd/mm/yyyy)	
	Start Date	Stop Date

•

Actions taken with the suspected medication: check all that apply

•

1) Was Exjade discontinued?

Yes - Date of Exjade discontinuation: ___/___/___ (dd/mm/yyyy)

- Has serum creatinine returned to baseline after discontinuation? **Yes**

No **Unknown**

- Has Exjade been restarted? **Yes** **No**

If **Yes**, restart date: ___/___/___ (dd/mm/yyyy),

Dose: _____

Re-occurrence of serum creatinine increase? **Yes** **No**

Unknown

•

No - Has Exjade dose been reduced? **Yes** **No**

If **Yes**, reduction date: ___/___/___ (dd/mm/yyyy),

Dose: _____

- Has serum creatinine returned to baseline after reduction? **Yes**

No **Unknown**

•

•

2) Measurement of serum creatinine

Date	Serum creatinine values	Unit	Reference Range

<i>[@ treatment start, if available]</i>				
<i>[during treatment #1, if available]</i>				
<i>[during treatment #2, if available]</i>				
<i>[@ time of event]</i>				
<i>[follow-up measurement @ +30d]</i>				
<i>[follow-up measurement @ +60d]</i>				

-
- **3)Renal biopsy**
- Has a renal biopsy been performed? Yes No
- If **Yes**, please provide results
-
-

4) Measurement of serum ferritin

	Date	Serum ferritin values	Unit	Reference Range
<i>[@ treatment start, if available]</i>				
<i>[during treatment #1, if available]</i>				
<i>[during treatment #2, if available]</i>				
<i>[during treatment #3, if available]</i>				
<i>[@ time of event]</i>				
<i>[follow-up measurement]</i>				

- **Patient History:**
- Does the patient have a history of any of the following prior to the start of Exjade? **Check all that apply**
- Renal disease Congestive heart failure
- Diabetes mellitus Hypertension
- Autoimmune disease Disease of the prostate
- Other relevant history (*please specify*) None of the above
- _____
- _____
- _____
- _____
- _____

- **Concomitant medication:**
- Was the patient taking any of the following drugs? **Check all that apply**
- ACE inhibitors Diuretics Analgesics (e.g. COX-2)
- Immunosuppressants inhibitors, NSAIDs)
- None of the above
-
- List details for the above drugs as appropriate:

Drug	Route of administration	Dosing regimen or daily dose	Dates of treatment (dd/mm/yyyy)		Indication for use
			Start date	Stop date	

• **Renal Impairment or Failure checklist**

- In addition to collecting routine information for this adverse event, please ensure the following additional information is provided and/or confirmed.

• **Event Description:**

- Did the patient present with any of the following signs or symptoms? **Check all that apply**

- Fever
- Increased urinary output
- Pain upon urinating
- Dehydration
- Decreased urinary output
- Discolored urine
- Arthralgia
- Difficulty starting or maintaining urine
- Pain around costovertebral
- Edema
- Urinary urgency
- Skin rash
- Infections
- Flank pain
- Burning sensation upon urinating
- Change in size of urine stream
- None of the above

- Were any of the following diagnostic tests performed? **Check all that apply and please specify which test(s) and include dates, results and reference range for pre- and post- treatment values**

- Creatinine clearance
- 24-hour protein (proteinuria)
- Kidney biopsy
- BUN
- Albumin
- CT scan
- Serum creatinine
- Serum total protein
- Renal ultrasound
- Hemoglobin
- Myoglobin
- Cystoscopy
- Electrolytes
- CPK
- Echocardiogram
- Urinalysis
- Glomerular filtration rate
- Chest x-ray
- Metabolic Acidosis
- Blood pressure
- Abdominal x-ray
- Antinuclear antibodies
- C-reactive protein
- Magnetic resonance imaging
- Liver function tests
- Lipid levels
- Electrocardiogram
- Sedimentation rate
- Coagulation studies
- None of the above

-
- **Patient History:**
- Does the patient have a history of any of the following prior to the start of the suspect drug? **Check all that apply**
- Congestive heart failure
- Diabetes mellitus (Type I or Type II)
- Reflux nephropathy
- Renal disease (including nephrolithiasis)
- Autoimmune disease
- Hypertension
- Extensive burns syndrome
- Kidney or bladder problems/Stones
- Disease of the prostate
- Intravenous contrast material
- Other relevant history (*please specify*)
- Multiple myeloma
- Exposure to chemical dyes
- Urinary tract infection
- Myocardial infarction
- Thromboembolic disease
- Coronary artery disease
- Obstructive uropathy
- Hypercalcemia
- Sickle cell disease
- History of renal transplant
- Hyperuricemia
- Hepatorenal syndrome
- Renal arteries obstructions
- Hemolytic uremic syndrome
- Drug allergies (*please specify*)
- Dehydration
- Injury (crush or extensive blunt)
- Rhabdomyolysis
- Hemorrhage
- Polycystic kidney disease
- None of the above
-
- Was the patient taking any of the following drugs? **Check all that apply**
- ACE inhibitors (e.g. COX-2)
- Immunosuppressants (NSAIDS)
- Lithium
- Antimicrobials (e.g. penicillin,
- Calcium
- Aminoglycosides
- Angiotensin II receptor blockers
- Foscarnet
- Diuretics
- Antineoplastic agents
- Vitamin D3
- Herbal medication (please specify)
- Amphotericin
- Diuretics
- None of the above
- Analgesics inhibitors,
-
- sulfonamides)
- Mercury
- Gold
-

• **Liver injury checklist**

- In addition to collecting routine information for this adverse event, please ensure the following additional information is provided and/or confirmed.
-

• **Event Description:**

- 1. Diagnosis and date of diagnosis
- 2. Did the patient present with any of the following signs or symptoms? **Check all that apply**
- Jaundice
- Dark urine
- Pale stool
- Pruritus
- Nausea
- Ascites
- Fever
- Fatigue
- Bleeding (specify location)
- Other (specify)
- Asterixis (flapping tremor)
- Altered mental status
- Abdominal pain (specify location)
- Anorexia
- None
-
- 3. Were any of the following diagnostic tests performed?
- **► If yes, please specify the dates and results including reference range and pre- and post- treatment values.**
- Liver function tests

- Serology & PCR testings for Hepatitis A, B, C &/or E virus
- Autoantibody test
- Abdominal or hepatobiliary ultrasound
- Abdominal CT scan
- Liver biopsy
- Liver transplant (planned or completed)
- Other (specify)
- None
-
- **Does the patient have a history of any of the following prior to the start of the suspect drug? Check all that apply and include date(s) of onset as well as status (i.e. active/inactive) and details**
- Previously elevated liver enzymes Tattoos
- Hepatitis Transfusion or blood product administration
- Other hepatobiliary disease or dysfunction Gilbert's disease
- Autoimmune disease Alcohol intake
- Active pancreatitis Drug abuse
- Diabetes mellitus (Type I or II) Foreign travel
- Non alcoholic steatohepatitis Active gall bladder disease
- None Other (specify)
- **Has the patient recently (i.e. within the past 6 months) taken any of the following? Check all that apply**
- Sulfonamides Furosemide ACE Inhibitors
- Valproic acid NSAIDS (e.g. ibuprofen) Estrogens (oral contraceptives)
- Metronidazole Acetaminophen/Paracetamol Amiodarone
- COX II inhibitors(e.g. celecoxib) Tetracycline Steroids
- Thiazide diuretics 6-Mercaptopurine Statins
- Nicotinic acid Methotrexate Other (specify)
- None
-
- **Exjade Gastrointestinal Ulcers & Bleed checklist**

- In addition to collecting routine information for this adverse event, please ensure the following additional information is provided and/or confirmed.
-

Event Description:

- Did the patient experience any of the following signs or symptoms before the GI bleed/ulcer developed? **Check all that apply & specify time to onset from first starting Exjade, time of occurrence during the day in relation to Exjade ingestion, severity, and frequency, if applicable**
-

Symptom	Time to onset from first starting Exjade	Time of occurrence during the day in relation to Exjade ingestion	Severity (mild, moderate, severe)	Frequency (e.g. daily, once weekly, three times monthly)
<input type="checkbox"/> Nausea				
<input type="checkbox"/> Abdominal pain				

• **Event Description:**

• Which of the following describes the hearing loss? **Check all that apply**

• **Unilateral hearing loss**

• or

• **Bilateral hearing loss**

• **Sensorineural hearing loss**

• or

• **Conductive hearing loss**

• Further description of the event (if necessary): _____

• _____

• _____

• _____

• Were any relevant investigations performed (e.g. audiometry testing or reports from specialists if consulted)?

• **Yes**, Test: _____ Date: ___/___/___ (dd/mm/yyyy)

Results: _____

• Test: _____ Date: ___/___/___ (dd/mm/yyyy)

Results: _____

• Test: _____ Date: ___/___/___ (dd/mm/yyyy)

Results: _____

• Test: _____ Date: ___/___/___ (dd/mm/yyyy)

Results: _____

• **No** **Unknown**

• **Patient History:**

• Does the patient have a history of **Ear problems** prior to the start of the suspect drug? **Yes** **No**

• **If yes, please specify:**

Other ear disorders (Please specify):

• _____

• _____

• _____

• _____

• _____

• _____

• **Follow-up:**

• **1) Was Exjade discontinued?**

• **Yes** - Was there any improvement in the hearing loss after discontinuation? **Yes** **No**

• - Has Exjade been restarted? **Yes** **No**

• If **Yes**, restart date: ___/___/___ (dd/mm/yyyy),

Dose: _____

• Re-occurrence of hearing loss? **Yes** **No**

• **No** - Has Exjade dose been reduced? **Yes** **No**

• If **Yes**, reduction date: ___/___/___ (dd/mm/yyyy),

Dose: _____

• - Was there any improvement in the hearing loss after reduction? **Yes** **No**

• **No**

• **2) Measurement of serum ferritin**

	Date	Serum ferritin values	Unit	Reference Range
[@ treatment start, if available]				
[during treatment #1, if available]				
[during treatment #2, if available]				
[during treatment #3, if available]				
[@ time of event]				
[follow-up measurement]				

-
- **Exjade Lens Opacities/Cataracts checklist**

- In addition to collecting routine information for this adverse event, please ensure the following additional information is provided and/or confirmed.

- **Event Description:**

Which of the following describes the lens opacity? **Check all that apply**

Unilateral
 or
 Bilateral

Punctuate lens opacities
 or
 Complete cataract formation

Further description of the lens opacity (e.g. size):

- Were any relevant investigations performed (e.g. ophthalmology testing or reports from specialists if consulted)?

Yes, Test: _____ Date: ___/___/___ (dd/mm/yyyy)

Results: _____

Test: _____ Date: ___/___/___ (dd/mm/yyyy)

Results: _____

Test: _____ Date: ___/___/___ (dd/mm/yyyy)

Results: _____

Test: _____ Date: ___/___/___ (dd/mm/yyyy)

Results: _____

No Unknown

- **Patient History:**

Does the patient have a history of **Lens opacities / Cataracts** prior to the start of the suspect drug?
 Yes No

If yes, please specify:

Other eye disorders (Please specify):

- _____
- _____
- **Follow-up:**
- **1) Was Exjade discontinued?**
- **Yes** - Was there any improvement in the lens opacity after discontinuation? **Yes** **No**
- - Has Exjade been restarted? **Yes** **No**
- If **Yes**, restart date: ___/___/___ (dd/mm/yyyy),
- Dose: _____
- Re-occurrence of lens opacity? **Yes** **No**
- **No** - Has Exjade dose been reduced? **Yes** **No**
- If **Yes**, reduction date: ___/___/___ (dd/mm/yyyy),
- Dose: _____
- - Was there any improvement in the lens opacity after reduction? **Yes** **No**

2) Measurement of serum ferritin

	Date	Serum ferritin values	Unit	Reference Range
<i>[@ treatment start, if available]</i>				
<i>[during treatment #1, if available]</i>				
<i>[during treatment #2, if available]</i>				
<i>[during treatment #3, if available]</i>				
<i>[@ time of event]</i>				
<i>[follow-up measurement]</i>				

Exjade Severe Skin Reaction Checklist

- In addition to collecting routine information for this adverse event, please ensure the following additional information is provided.

Event Description:

Did the patient present with any of the following signs or symptoms? **Check all that apply**

<input type="checkbox"/> Infiltration	<input type="checkbox"/> Itching	<input type="checkbox"/> Headache
<input type="checkbox"/> Blistering of rash	<input type="checkbox"/> Joint aches	<input type="checkbox"/> Body aches
<input type="checkbox"/> Desquamation (skin loss)/skin peeling	<input type="checkbox"/> Visual symptoms	<input type="checkbox"/> Electrolyte imbalances
<input type="checkbox"/> Nikolsky's symptom	<input type="checkbox"/> General ill feeling	<input type="checkbox"/> Eating/Swallowing difficulties
<input type="checkbox"/> Involvement of mucous membrane	<input type="checkbox"/> Fever	<input type="checkbox"/> Genital lesions
<input type="checkbox"/> Rash	<input type="checkbox"/> Chills	<input type="checkbox"/> Necrosis

Was the rash associated with any other systemic symptoms or abnormalities?
the above

Yes (please describe) No Unknown Other

(please specify)

Time to onset of general symptoms after starting suspected medication?

Time to onset of cutaneous symptoms after starting suspected medication?

Description of lesion(s) on the skin: (type [erythematic, papules, plaques, eczema, blisters, etc. with estimated % of body surface], topography [sun exposed areas only, trunk and upper extremities, face, etc.], start and stop date(s) of skin lesion[s])

Was there a final diagnosis?

Yes (please describe and whether it was confirmed by a dermatologist) **No** **Unknown**

Were any of the following diagnostic tests performed? **Check all that apply and please specify which test(s), dates and results**

- Skin lesion biopsy
- Immunofluorescence testing
- Microscopic examination of skin
- Genetic test
 - ▶ Was genotyping of HLA (Human Leukocyte Antigen) done? Yes No Unknown
 - ▶ Was HLA-B*1502 allele positive? Yes No Unknown
 - ▶ Was HLA-A*3101 allele positive? Yes No Unknown
- None of the above

Relevant medical history (concurrent and pre-existing conditions)

(Please specify medical condition and date of onset)

Does the patient have a history of any of the following prior to the start of the suspect drug? **Check all that apply**

- Herpes simplex
- Streptococcal infection
- Immunization (please specify)
- Drug allergy (please specify)
- HIV
- Influenza
- Typhoid
- Excessive UV light exposure
- Carrying HLA-B12 gene
- Graft-versus-host disease
- Staphylococcal infection
- Mycoplasma pneumonia
- Bone marrow or organ transplant
- Non-drug allergy (please specify)
- Hepatitis
- Diphtheria
- Radiation therapy
- Systemic lupus erythematosus
- None of the above
- Other relevant history (please specify)

Was the patient taking any of the following drugs? **Check all that apply**

- Anticonvulsants (e.g. phenytoin)
- NSAIDs
- Sulfonamide antibiotics
- Allopurinol
- Non-sulfonamide antibiotics
- Acetaminophen/Paracetamol
- Barbiturates
- Corticosteroids
- None of the above

Please indicate the treatment (if any) provided to the patient for this event.

Please specify treatment (corticosteroids, cyclophosphamide, other)

Drug	Dose	Dates (Start-Stop)
------	------	--------------------

Outcome of event (include date if appropriate):

Action taken with Deferasirox with regard to event (include date if appropriate):